BACKGROUND: miR-143 and miR-145 are believed to function as colon cancer tumor suppressors, as they inhibit colon cancer cell growth and are downregulated in sporadic colonic tumors. We speculated that miR-143 and miR-145 might also be downregulated and contribute to malignant transformation of colonic epithelium in longstanding ulcerative colitis (UC). METHODS: Biopsies were obtained 20 cm proximal to the anus from individuals with quiescent UC and from normal controls. RNA and proteins were extracted and measured. miR-143 and miR-145 were quantified by real-time polymerase chain reaction (PCR) and miR-145 was also assessed by in situ hybridization. Putative targets of these miRNAs, K-RAS, API5, MEK-2 (miR-143), and IRS-1 (miR-145) were determined by western blotting. To assess the effects of miR-143 and miR-145 on these predicted targets, HCT116 and HCA-7 colorectal cancer cells were transfected with miR-143 and miR-145 and expression levels of these proteins were measured. RESULTS: In UC, miR-143 and miR-145 were significantly downregulated 8.3-fold (3.4-20.1) (P < 0.0001) and 4.3-fold (2.3-7.8) (P < 0.0001), respectively, compared to normal colon. In contrast, IRS-1, K-RAS, API5, and MEK-2 were upregulated in UC, consistent with their assignments as targets of these miRNAs. Furthermore, transfected miR-143 and miR-145 significantly downregulated these proteins in HCT116 or HCA-7 cells. CONCLUSIONS: Compared to normal colonic mucosa, in chronic UC miR-143 and miR-145 were significantly downregulated and their predicted targets, IRS-1, K-RAS, API5, and MEK-2 were upregulated. We postulate that loss of these tumor suppressor miRNAs predispose to chronic inflammation and neoplastic progression in IBD.
BACKGROUND:miR-143 and miR-145 are believed to function as colon cancer tumor suppressors, as they inhibit colon cancer cell growth and are downregulated in sporadic colonic tumors. We speculated that miR-143 and miR-145 might also be downregulated and contribute to malignant transformation of colonic epithelium in longstanding ulcerative colitis (UC). METHODS: Biopsies were obtained 20 cm proximal to the anus from individuals with quiescent UC and from normal controls. RNA and proteins were extracted and measured. miR-143 and miR-145 were quantified by real-time polymerase chain reaction (PCR) and miR-145 was also assessed by in situ hybridization. Putative targets of these miRNAs, K-RAS, API5, MEK-2 (miR-143), and IRS-1 (miR-145) were determined by western blotting. To assess the effects of miR-143 and miR-145 on these predicted targets, HCT116 and HCA-7 colorectal cancer cells were transfected with miR-143 and miR-145 and expression levels of these proteins were measured. RESULTS: In UC, miR-143 and miR-145 were significantly downregulated 8.3-fold (3.4-20.1) (P < 0.0001) and 4.3-fold (2.3-7.8) (P < 0.0001), respectively, compared to normal colon. In contrast, IRS-1, K-RAS, API5, and MEK-2 were upregulated in UC, consistent with their assignments as targets of these miRNAs. Furthermore, transfected miR-143 and miR-145 significantly downregulated these proteins in HCT116 or HCA-7 cells. CONCLUSIONS: Compared to normal colonic mucosa, in chronic UC miR-143 and miR-145 were significantly downregulated and their predicted targets, IRS-1, K-RAS, API5, and MEK-2 were upregulated. We postulate that loss of these tumor suppressor miRNAs predispose to chronic inflammation and neoplastic progression in IBD.
Authors: X Chen; X Guo; H Zhang; Y Xiang; J Chen; Y Yin; X Cai; K Wang; G Wang; Y Ba; L Zhu; J Wang; R Yang; Y Zhang; Z Ren; K Zen; J Zhang; C-Y Zhang Journal: Oncogene Date: 2009-01-12 Impact factor: 9.867
Authors: Yi Yang; Raghothama Chaerkady; Kumaran Kandasamy; Tai-Chung Huang; Lakshmi Dhevi N Selvan; Sutopa B Dwivedi; Oliver A Kent; Joshua T Mendell; Akhilesh Pandey Journal: Mol Biosyst Date: 2010-06-14
Authors: David M Su; Qiuyang Zhang; Xuexi Wang; Ping He; Yuelin Jack Zhu; Jianxiong Zhao; Owen M Rennert; Yan A Su Journal: Mol Cancer Ther Date: 2009-04-21 Impact factor: 6.261
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Nicole M Ramocki; Heather R Wilkins; Scott T Magness; James G Simmons; Brooks P Scull; Ginny H Lee; Kirk K McNaughton; P Kay Lund Journal: Endocrinology Date: 2007-10-04 Impact factor: 4.736
Authors: Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan Journal: Nat Med Date: 2009-11-08 Impact factor: 53.440
Authors: Hongyan Zhu; Urszula Dougherty; Victoria Robinson; Reba Mustafi; Joel Pekow; Sonia Kupfer; Yan Chun Li; John Hart; Kathleen Goss; Alessandro Fichera; Loren Joseph; Marc Bissonnette Journal: Mol Cancer Res Date: 2011-06-08 Impact factor: 5.852
Authors: Adam M Zahm; Nicholas J Hand; Daphne M Tsoucas; Claire L Le Guen; Robert N Baldassano; Joshua R Friedman Journal: J Crohns Colitis Date: 2014-03-07 Impact factor: 9.071
Authors: Joel Pekow; Alan L Hutchison; Katherine Meckel; Kymberly Harrington; Zifeng Deng; Nitya Talasila; David T Rubin; Stephen B Hanauer; Roger Hurst; Konstantin Umanskiy; Alessandro Fichera; John Hart; Aaron R Dinner; Marc Bissonnette Journal: Inflamm Bowel Dis Date: 2017-08 Impact factor: 5.325
Authors: Xiaochang Xue; Anthony T Cao; Xiaocang Cao; Suxia Yao; Eric D Carlsen; Lynn Soong; Chang-Gong Liu; Xiuping Liu; Zhanju Liu; L Wayne Duck; Charles O Elson; Yingzi Cong Journal: Eur J Immunol Date: 2014-01-13 Impact factor: 5.532
Authors: Lenka Koci; Katarina Chlebova; Martina Hyzdalova; Jirina Hofmanova; Miroslav Jira; Petr Kysela; Alois Kozubik; Zdenek Kala; Pavel Krejci Journal: Oncol Lett Date: 2012-02-03 Impact factor: 2.967
Authors: Mehmet Coskun; Jacob Tveiten Bjerrum; Jakob Benedict Seidelin; Ole Haagen Nielsen Journal: World J Gastroenterol Date: 2012-09-14 Impact factor: 5.742
Authors: M Iborra; F Bernuzzi; C Correale; S Vetrano; G Fiorino; B Beltrán; F Marabita; M Locati; A Spinelli; P Nos; P Invernizzi; S Danese Journal: Clin Exp Immunol Date: 2013-08 Impact factor: 4.330